Dr. Bogaerts Cardiologie SRL

Dr. Bogaerts Cardiologie reported total assets of 118,586 € at the end of the 2025 financial year (annual accounts filed with the NBB on 29 Jul 2026).

Company number (CBE) 0803.845.433 · VAT BE0803845433
1790 Affligem
active in Research and experimental development on biotechnology (NACE 72101)
operating since 11 Jul 2023 (≈ 3 yrs)
Public Public page: latest year only. The score, history and details open with a free account. Create a free account
Idonis solidity score
EDCBA

The score of Dr. Bogaerts Cardiologie shows with a free account.

See the score
Profile
SRL since 2023
Components
  • Summary? / 5
    • Balance sheet strength
    • Liquidity
    • Repayment capacity
    • Profitability
    • Trajectory
    • Compliance and register
  • Position in its sectorvs peers
  • Supplier creditat 30 d
  • Borrowing capacityborrowable
  • Valuationcentral

Visible once signed in: create your account, the 14-day Pro trial is free.

Detail

Key figures 2025

Net result55,308 €
Equity101,482 €
Cash83,343 €
EBITDA69,422 €
Total assets118,586 €
The line marks its sector median: 60.4% (425 companies).

Accounts of the company itself (not consolidated).

The full file covers 2 financial years; a free account shows 2. →

Deterministic calculation on the filed accounts, no AI. Dispute the score or report an error

Dr. Bogaerts Cardiologie's annual accounts

20252024
Net result55,308 €
Equity101,482 €
Cash83,343 €
EBITDA69,422 €
Total assets118,586 €

Filed annual accounts

  • Year ended 31 Dec 2025filed on 29 Jul 2026
  • Year ended 31 Dec 2024filed on 14 Jul 2025

Dr. Bogaerts Cardiologie's financial analysis

Management and control of Dr. Bogaerts Cardiologie

1 active director(s) in the register.

Dr. Bogaerts Cardiologie's shareholders and holdings →

Dr. Bogaerts Cardiologie's publications in the Belgian Gazette

Company number, VAT number and registered office

Company number (CBE)
0803.845.433
VAT number
BE0803845433
Peppol
Not found on Peppol as of 10 Nov 2026 · Check
Legal form
SRL
Incorporated
11 Jul 2023
Registered office
1790 Affligem
Latest accounts
2025 · filed on 29 Jul 2026
Activity
Research and experimental development on biotechnology (NACE 72101)

Dr. Bogaerts Cardiologie (SRL) has been based in Affligem since 2023, active in: research and experimental development on biotechnology. For 2025, it reports a net profit of 55,308 € and equity of 101,482 €; its revenue is not published. Its solvency stands at 85.6%, above the median of its sector (60.4%).

Guide: Reading Belgian SME accounts: the five figures that count →

Companies similar to Dr. Bogaerts Cardiologie

Companies in the same business, of comparable size and area, outside its group.

Frequently asked questions about Dr. Bogaerts Cardiologie

What is the revenue of Dr. Bogaerts Cardiologie?

Dr. Bogaerts Cardiologie files its accounts in a format where revenue is optional: it is not published for 2025.

What is the VAT number of Dr. Bogaerts Cardiologie?

In Belgium, the VAT number is the company number prefixed with BE: BE0803845433 for Dr. Bogaerts Cardiologie, if the company is VAT-registered. Its company number (CBE) is 0803.845.433.

Where is the registered office of Dr. Bogaerts Cardiologie?

According to the CBE register, the registered office of Dr. Bogaerts Cardiologie is in 1790 Affligem.

What is the equity of Dr. Bogaerts Cardiologie?

At the close of the 2025 financial year, the equity of Dr. Bogaerts Cardiologie amounts to 101,482 €, a solvency of 85.6% of total assets.

Who manages Dr. Bogaerts Cardiologie?

The register lists 1 active mandates at Dr. Bogaerts Cardiologie. Names and roles are in the full file, with the deeds published in the Belgian Gazette.

Idonis

The full file of Dr. Bogaerts Cardiologie

Directors and mandates, ownership network, Gazette deeds, ten years of accounts and ratios, Excel export, and Idonis's analysis in one question.

Open the full file →
Free account in 30 seconds, by email. No bank card.
Sources : Annual accounts — NBB ↗ Register — CBE ↗ Deeds — Belgian Gazette ↗ · Updated on 03 Aug 2026

No credit card, no commitment.

What each plan unlocks →